DRD2 and Parkinson disease: Moreover, D2R and their regulatory molecules are known therapeutic targets, whereas dysregulation of dopaminergic signaling is associated with neurological and psychiatric diseases such as Parkinson’s disease (PD), schizophrenia, and depression [8].